Sanofi, Regeneron expand partnership in deal worth up to $8 billion

Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.